Martin Hoglund
Overview
Explore the profile of Martin Hoglund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
4284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brune M, Kiss T, Anderson H, Nicklasson M, Delage R, Finke J, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1676-1682.
PMID: 39223244
The aim of this prospective, international multicenter, pseudorandomized study comparing RICT HCT to standard-of-care chemotherapy in intermediate- or high-risk AML patients 50-70 years using the donor versus no-donor concept. Part...
2.
Iribarren C, Levedahl K, Atanasoai I, Mattsson M, Hoglund M, Soderlund S, et al.
J Mol Diagn
. 2024 Jun;
26(9):792-804.
PMID: 38925457
Mastocytosis is a heterogeneous disorder characterized by abnormal mast cell accumulation, in which the clinical severity may be explained by distinct molecular mechanisms. This study aimed to explore plasma protein...
3.
Roth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, et al.
Am J Hematol
. 2024 Jun;
99(9):1768-1777.
PMID: 38884175
Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low-volume self-administration every 4 weeks. COMMODORE 2 (NCT04434092) is a global, randomized, open-label, multicenter,...
4.
Abe C, Keto J, Lilja M, Konradsen M, Mesterton J, Hoglund M, et al.
Leuk Lymphoma
. 2024 Jun;
65(10):1493-1501.
PMID: 38861379
Since 1980's, the established/standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). We compared the 7 + 3 regimen in older secondary/high-risk AML...
5.
Alvez M, Edfors F, Von Feilitzen K, Zwahlen M, Mardinoglu A, Edqvist P, et al.
Nat Commun
. 2023 Jul;
14(1):4308.
PMID: 37463882
A comprehensive characterization of blood proteome profiles in cancer patients can contribute to a better understanding of the disease etiology, resulting in earlier diagnosis, risk stratification and better monitoring of...
6.
Transparent Wood Biocomposite of Well-Dispersed Dye Content for Fluorescence and Lasing Applications
Hoglund M, Baitenov A, Berglund L, Popov S
ACS Appl Opt Mater
. 2023 May;
1(5):1043-1051.
PMID: 37255504
Aggregation-induced quenching often restricts emissive performance of optically active solid materials with embedded fluorescent dyes. Delignified and nanoporous wood readily adsorbs organic dyes and is investigated as a host material...
7.
The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study
Dahlen T, Flygt H, Lubking A, Olsson-Stromberg U, Wennstrom L, Dreimane A, et al.
Leukemia
. 2023 Apr;
37(5):1156-1159.
PMID: 37037908
No abstract available.
8.
Stratmann S, Vesterlund M, Umer H, Eshtad S, Skaftason A, Herlin M, et al.
Leukemia
. 2022 Dec;
37(3):550-559.
PMID: 36572751
Despite improvement of current treatment strategies and novel targeted drugs, relapse and treatment resistance largely determine the outcome for acute myeloid leukemia (AML) patients. To identify the underlying molecular characteristics,...
9.
Bratulic S, Limeta A, Dabestani S, Birgisson H, Enblad G, Stalberg K, et al.
Proc Natl Acad Sci U S A
. 2022 Dec;
119(50):e2115328119.
PMID: 36469776
Cancer mortality is exacerbated by late-stage diagnosis. Liquid biopsies based on genomic biomarkers can noninvasively diagnose cancers. However, validation studies have reported ~10% sensitivity to detect stage I cancer in...
10.
Huuhtanen J, Ilander M, Yadav B, Dufva O, Lahteenmaki H, Kasanen T, et al.
J Clin Invest
. 2022 Sep;
132(17).
PMID: 36047494
In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-α is one promising...